Modern modes of chronic hepatitis C treatment

Modern modes of chronic hepatitis C treatment

The aim of review. To highlight up-to-date modes of chronic hepatitis C treatment.Original positions. Nowadays conventional «gold standard» treatment of chronic HCV-infection is antiviral therapy by pegilated interferon and ribavirin combination. Recently principles of antiviral treatment were serio...

Full description

Saved in:

Bibliographic Details
Main Authors:	V. T. Ivashkin, M. V. Mayevskaya, M. A. Morozova, Ye. O. Lyusina
Format:	Article
Language:	Russian
Published:	Gastro LLC 2012-02-01
Series:	Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:	hepatitis c antiviral therapy virologic response protease inhibitors telaprevir boceprevir
Online Access:	https://www.gastro-j.ru/jour/article/view/1260
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Two ways to one goal: new strategy of antiviral therapy for chronic hepatitis C
by: S. N. Batskikh
Published: (2012-11-01)

Betaleukin in therapy of chronic hepatitis C
by: E. S. Romanova, et al.
Published: (2014-10-01)

http://www.aulamedica.es/fh/pdf/1129.pdf
by: R. López-Sepúlveda, et al.
Published: (2014-01-01)

Boceprevir and Telaprevir: Clinical Efficacy, Safety and Drug-Drug Interactions
by: A. V. Nikitin
Published: (2020-05-01)

Telaprevir: options of application in separate patient groups
by: M. V. Mayevskaya, et al.
Published: (2013-10-01)

The use of telaprevir for the treatment of hepatitis C in patients undergoing liver transplantation (Literature review and clinical experience)
by: M. Sh. Khubutiya, et al.
Published: (2016-02-01)

Triple antiviral therapy in patient with liver cirrhosis: complications and options of pharmacological treatment
by: M. V. Mayevskaya, et al.
Published: (2014-08-01)

Antiviral therapy for chronic hepatitis C: is there a time to change existing standards?
by: D. T. Abdurakhmanov
Published: (2009-02-01)

Modern modes of chronic hepatitis B treatment in daily clinical practice
by: M. V. Mayevskaya, et al.
Published: (2014-11-01)

NS5A replication complex inhibitor daclatasvir in the basis of chronic hepatitis C interferon-free therapy
by: M. V. Mayevskaya, et al.
Published: (2015-12-01)

Effectiveness and Safety of Direct-Acting Antivirals in the Treatment of Chronic Hepatitis C: A Real-life Study in Northeastern Brazil
by: Elodie Bomfim Hyppolito, et al.
Published: (2024-11-01)

PERSONALIZED APPROACH TO TREATING CHRONIC HEPATITIS C IN CHILDREN
by: T. A. Skvortsova, et al.
Published: (2014-03-01)

Antiviral therapy of hepatitis C with 1 genotype after liver transplantation
by: O. M. Tsiroulnikova, et al.
Published: (2018-09-01)

Reply to correspondence on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”
by: Chen-Hua Liu, et al.
Published: (2025-04-01)

Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study
by: Shou-Wu Lee, et al.
Published: (2025-07-01)

Emerging therapies for the treatment of hepatitis C
by: Christian M Lange, et al.
Published: (2013-09-01)

Comparative analysis of the safety of triple therapy with telaprevir between HCV monoinfected and HIV coinfected patients
by: C. Sangrador Pelluz, et al.
Published: (2014-01-01)

Incidence and Factors of Hepatocellular Carcinoma in Hepatitis C Virus Patients Achieving Sustained Virological Response After Direct-Acting Antiviral Treatment
by: Juferdy Kurniawan Kurniawan, et al.
Published: (2024-12-01)

Real-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C — The TEPS Study
by: T. Berg, et al.
Published: (2019-01-01)

Lack of Tissue Virological Response as a Predictor of Relapse in Chronic Hepatitis D after Completion Bulevirtide Therapy
by: P. O. Bogomolov, et al.
Published: (2024-12-01)

The efficacy and safety of antiviral drugs of direct action in liver recipients with recurrence of chronic hepatitis C genotype 1 after transplantation
by: О. M. Tsiroulnikova, et al.
Published: (2019-01-01)

Effectiveness and safety of sofosbuvir/velpatasvir in chronic hepatitis C virus infection of Bangladeshi children
by: Salahuddin Mahmud, et al.
Published: (2025-06-01)

Reflex testing for anti-HDV in HBsAg-positive patients offers high diagnostic yield in a large Central European tertiary care center
by: Johannes Bernhard, et al.
Published: (2024-10-01)

Therapy of chronic hepatitis C: Virologic response monitoring
by: Kuljić-Kapulica Nada, et al.
Published: (2010-01-01)

RESULTS OF THE USE OF SOFOSBUVIR IN COMBINATION WITH LEDIPASVIR OR DACLATASVIR FOR CHRONIC HEPATITIS C TREATMENT IN THE REPUBLIC OF BELARUS
by: S. V. Zhavoronok, et al.
Published: (2018-10-01)

Genotype 3 is linked to worse liver disease progression in hepatitis C patients even after SVR following DAA therapy
by: Xiping Ran, et al.
Published: (2025-02-01)

Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter?
by: Carlo Smirne, et al.
Published: (2024-12-01)

Liver fibrosis assessment by transient elastography in patients with liver cirrhosis after hepatitis C virus eradication
by: E. A. Nabatchikova, et al.
Published: (2020-03-01)

Efficacy and safety of sofosbuvir plus daclatasvir in hemodialysis patients with genotype 1b or 2a hepatitis C virus infection: a single-arm, prospective real-world study
by: Kaili Wang, et al.
Published: (2025-07-01)

SVR timelines in hepatitis - C irrespective of viral genotype: An Indian perspective
by: Nambaru Vidya Sagar, et al.
Published: (2025-04-01)

Safety and efficacy of telaprevir in treatment of a chronic hepatitis C in patients of the Russian population included in early access program study
by: D. T. Abrurakhmanov, et al.
Published: (2014-07-01)

B-cell non-Hodgkin's lymphoma in the patient with chronic hepatitis C and mixed cryoglobulinemia
by: V. S. Adonyeva, et al.
Published: (2015-03-01)

Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial
by: Hyung Joon Yim, et al.
Published: (2025-07-01)

The prognostic value of ferritinemia level in patients with chronic hepatitis C
by: N. C. Sargsyants, et al.
Published: (2013-07-01)

Experience of effective antiviral therapy in a liver recipient with recurrent HCV infection genotype 1
by: D. V. Umrik, et al.
Published: (2019-01-01)

Hepatitis C Virus Resistance-Associated Substitutions in Mexico
by: Alexis Jose-Abrego, et al.
Published: (2025-01-01)

New drugs in the treatment of chronic hepatitis C
by: R. Jimenez Galan, et al.
Published: (2014-04-01)

Impact of Hepatitis C Virus Clearance on Cardiovascular Risk: A Real‐World Experience From the Nationwide Taiwan Hepatitis C Virus Registry
by: Ping‐Jen Hu, et al.
Published: (2025-08-01)

Effectiveness and safety of narlaprevir in real clinical practice of chronic hepatitis C
by: V. V. Basina, et al.
Published: (2019-12-01)

TREATMENT OF HEPATITIS C WITHOUT INTERFERON IN PATIENTS UNDERGOING LIVER TRANSPLANTATION
by: M. Sh. Khubutia, et al.
Published: (2015-10-01)